Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.13 | N/A | -81.68% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.13 | N/A | -81.68% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management acknowledged challenges faced during the quarter. They highlighted the importance of adapting to market dynamics.
Management expressed concerns about current market conditions.
They emphasized the need for strategic adjustments moving forward.
The earnings report indicates that Arrowhead Pharmaceuticals faced significant challenges this quarter, particularly reflected in their EPS miss. The stock reacted negatively, dropping 3.9%, likely due to investor concerns about the company's performance and lack of guidance. Without clear direction from management, uncertainty may linger among investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEAGATE TECHNOLOGY H
Feb 4, 2019